Drug Development

Protocols: Editas adds CRISPR/Cas9 IP; biosimilars make fresh gains in U.S. market

Editas $EDIT has picked up some fresh CRISPR/Cas9 IP from Mass General. The gene editing pioneer, which has focused on adding fresh tech in the race to get programs into the clinic, says the deal adds “high-fidelity Cas9 nucleases and Cas9 PAM variants that will enable the Company to address an expanded range of genetically-defined diseases with the potential for enhanced specificity.”

Anyone looking for fresh evidence of the impact biosimilars will have on branded drugs should look to the latest news from CVS, which just replaced Sanofi’s Lantus with a cheaper copycat from Eli Lilly on its formulary. Drug buyers will have little trouble forcing patients to take less expensive biosimilars in the U.S., which will help accelerate rapid adoption.

The private equity group Velocity Fund Partners has acquired the Philadelphia-based CRO Indipharm and relaunched it as InClinica.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 44,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Sr. Manager, Regulatory Affairs, CMC
CytomX Therapeutics San Francisco, CA
Marketing Associate - Demand Generation
Catalytic Data Science Charleston, SC
Associate Principal, Life Sciences Partnerships
Flatiron Health New York City or San Francisco

Visit Endpoints Careers ->